complicated manufacturing processes and lead time to treat patients.

TRIGR is building an asset portfolio of clinical-stage and pre-clinical antibodies that will represent the next wave in cancer immunotherapy. they currently have partnered with innovative R&D companies, such as ABL Bio in South Korea, and will develop selected ABL programs into approved immunotherapies worldwide. TRIGR’s diversified pipeline currently consists of immunotherapies against novel and validated targets that have the potential to overcome and modulate biological barriers (e.g. tumor micro-environment) to result in successful treatment outcomes.